id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1691-0007,FDA,FDA-2013-E-1691,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-02T04:00:00Z,2016,8,2016-08-02T04:00:00Z,,2016-08-02T23:57:39Z,,0,0,090000648214fd37
FDA-2013-E-1691-0006,FDA,FDA-2013-E-1691,"Determination of Regulatory Review Period for Purposes of Patent
Extension; KADCYLA",Notice,Determinations,2015-12-28T05:00:00Z,2015,12,2015-12-28T05:00:00Z,2016-02-27T04:59:59Z,2015-12-28T19:47:01Z,2015-32475,0,0,0900006481dd3e06
FDA-2013-E-1691-0005,FDA,FDA-2013-E-1691,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-12T05:00:00Z,2015,11,2015-11-12T05:00:00Z,,2015-11-12T13:36:52Z,,0,0,0900006481d3867a
FDA-2013-E-1691-0004,FDA,FDA-2013-E-1691,Letter from the U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-03-25T04:00:00Z,2015,3,2015-03-25T04:00:00Z,,2015-03-25T16:39:15Z,,0,0,0900006481a64245
FDA-2013-E-1691-0003,FDA,FDA-2013-E-1691,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-27T04:00:00Z,2014,5,2014-05-27T04:00:00Z,,2014-05-27T15:42:47Z,,0,0,0900006481715d46
FDA-2013-E-1691-0001,FDA,FDA-2013-E-1691,U.S.. Patatent and Trademark Office - Letter,Other,Letter(s),2013-12-26T05:00:00Z,2013,12,2013-12-26T05:00:00Z,,2013-12-26T14:10:36Z,,0,0,09000064814dc7e9
FDA-2013-E-1691-0002,FDA,FDA-2013-E-1691,"Morrison & Foerster LLP (on behalf of Genenetech, Inc) - Patent Term Application",Other,Application,2013-12-26T05:00:00Z,2013,12,2013-12-26T05:00:00Z,,2013-12-26T14:27:36Z,,0,0,09000064814db700